TITLE 7 HEALTH
CHAPTER 32 ALCOHOL
AND DRUG ABUSE
PART 8 OPIOID
TREATMENT PROGRAMS
7.32.8.1 ISSUING AGENCY: department
of Health; Behavioral Health Services Division.
[7.32.8.1 NMAC - N, 11-30-05]
7.32.8.2 SCOPE: This rule is applicable to
opioid treatment programs. These
regulations are not intended to preempt county or municipal ordinances that
supplement and do not conflict with these regulations. County and municipal ordinances are preempted
when they conflict with these regulations.
[7.32.8.2 NMAC - N, 11-30-05]
7.32.8.3 STATUTORY
AUTHORITY: Department
of Health Act, NMSA 1978 Section 9-7-6 (E).
[7.32.8.3 NMAC - N, 11-30-05]
7.32.8.4 DURATION: Permanent.
[7.32.8.4 NMAC - N, 11-30-05]
7.32.8.5 EFFECTIVE
DATE: 11-30-05, unless a later date is
cited at the end of a section.
[7.32.8.5 NMAC - N, 11-30-05]
7.32.8.6 OBJECTIVE: This rule establishes standards
for opioid treatment programs to be consistent with the SAMHSA/CSAT regulations
and the OTP accreditation requirements of nationally recognized accreditation
bodies approved by SAMSA/CSAT, such as CARF and JCAHO. The intent is to:
A. be consistent with, and
complimentary to, the substance abuse and mental health services
administration/center for substance abuse treatment (SAMHSA/CSAT) regulations,
and the OTP accreditation requirements of nationally recognized accreditation
bodies approved by SAMHSA/CSAT, such as commission on accreditation of
rehabilitation facilities (CARF) and the joint commission on accreditation of
healthcare organizations (JCAHO);
B. reduce the stigma sometimes
associated with opioid dependency treatment and ensure access to it comparable
to treatment availability for other chronic medical conditions;
C. consider the possible adverse impact
on communities in which OTP providers are located in making application
approval decisions, and to provide measures to promote mutually satisfactory
relationships between OTP providers and their communities.
[7.32.8.6 NMAC - N, 11-30-05]
7.32.8.7 DEFINITIONS:
A. “Accrediting bodies” means
nationally recognized organizations, such as the joint commission on
accreditation of healthcare organizations (JCAHO) and the commission on
accreditation of rehabilitation facilities (CARF), which promulgate standards
for OTPs that are approved by the substance abuse and mental health services
administration/center for substance abuse treatment (SAMHSA/CSAT), and offer
accreditation to programs that meet these standards.
B. “Administrative withdrawal”
means the procedure for withdrawal of a patient’s opioid treatment medication
coinciding with the patient’s involuntary discharge from opioid treatment,
typically resulting from non-payment of fees, violent or disruptive behavior or
incarceration or other confinement.
C. “Application
form” means the form created by the department of health, which must be
completed by a program sponsor who wishes to obtain approval to operate an
opioid treatment program.
D. “Approval”
and “approval to operate” means the written permission given by the
department of health to a program sponsor to operate an opioid treatment
program.
E. “Behavioral
health services division” (BHSD) is the
division of the New Mexico department of health that is the single state
authority for mental health and substance use treatment and prevention programs
and methadone authority.
F. “Comprehensive initial
assessment” means the collection and analysis of a patient’s social,
medical, psychological and treatment history.
G. “Comprehensive maintenance
treatment” means a program designed with the intention of lasting longer
than six months, for the purpose of maintaining the patient such that he/she
will be free of opioid withdrawal and cravings; such programs are typified by:
(1) dispensing or administering an opioid
treatment medication at stable dosage levels for a period in excess of 21 days
to an individual for opioid addiction; and
(2) providing medical, therapeutic and
supportive services to the individual with opioid dependence.
H. “Department of health” (DOH)
means the state of New Mexico department of health.
I. “Dispense” has the same
meaning as in section 61-11-2(I) NMSA as amended or renumbered.
J. “Diversion”
means the unauthorized transfer of an opioid agonist treatment medication, such
as a street sale.
K. “Dosage”
means the amount, frequency and number of doses of medication for an
individual.
L. “Dose”
means a single unit of opioid treatment medication.
M. “Illicit opioid
drug” means an illegally obtained opioid drug, such as heroin, that causes
dependence and reduces or destroys an individual’s physical, social,
occupational, or educational functioning, or misuse of legally prescribed
medication.
N. “Intake
screening” means determining whether an individual meets the initial
criteria for receiving opioid treatment.
O. “Long-term opioid treatment
withdrawal procedure” means a treatment program designed to dispense opioid
treatment medication to a patient in decreasing doses, after first possibly
achieving a stable dose, for a period of more than 30 days but less than 180
days as a method of bringing the individual to a drug-free state.
P. “Medical practitioner” means an
individual who:
(1) has been accredited through appropriate
national procedures as a health professional;
(2) fulfills the national requirements on
training and experience for prescribing procedures;
(3) is a registrant or a licensee, or a worker
who has been designated by a registered or licensed employer for the purpose of
prescribing procedures;
(4) may be a physician, physician’s
assistant, registered nurse, nurse practitioner, or licensed practical nurse.
Q. “Opioid
treatment” means:
(1)
opioid treatment withdrawal procedure/treatment; and
(2) comprehensive maintenance treatment.
R. “Opioid
treatment medication” means a prescription medication that is approved by
the U.S. food and drug administration under 21 U.S.C. section 355 and by the
code of federal regulations title 42, part 8.12 for use in the treatment of
opiate addiction.
S. “Opioid treatment program”
(OTP) means a single location at which opioid dependence treatment medication,
such as methadone and rehabilitative services, are provided to patients as a
substantial part of the activity conducted on the premises.
T. Opioid
treatment withdrawal procedure” is dispensing or administering an
opioid dependence treatment medication in decreasing medication levels to an
individual to alleviate adverse physical or psychological effects of withdrawal
from the continuous or sustained use of an opioid drug and as a method of
bringing the individual to a drug-free state.
U. “Physiologically dependent”
means physically addicted to an opioid drug, as manifested by the symptoms of
withdrawal in the absence of the opioid drug.
V. “Program clinician” means a
behavioral health clinician practicing at an opioid treatment program who is
licensed to practice substance abuse treatment in New Mexico
W. “Program medical director” means
a physician licensed to practice medicine in New Mexico, who assumes
responsibility for administering all medical services, either by performing
them directly or by delegating specific responsibility to authorized program
medical practitioners functioning under the medical director’s direct
supervision.
X. “Program sponsor” means the
person named in the application as responsible for the operation of the opioid
treatment program and who assumes responsibility directly, by personal
oversight, or through policy and procedure, or a combination of both, for the
acts and omissions of staff members or employees of the opioid treatment
program.
Y. “Short-term opioid treatment
withdrawal procedure” means a treatment program
designed to dispense opioid treatment medication to a patient in decreasing
doses, over a continuous period of 30 days or less,
as a method of bringing the individual to a drug-free state.
Z. “State methadone authority,” (SMA) means
the single state agency for substance abuse designated by the governor or
another appropriate official designated by the governor to exercise authority
within the state for governing treatment of opiate addiction with an opioid
drug. In New Mexico it is the department
of health, behavioral health services division.
AA. “Take-home medication” means one or more doses of an
opioid treatment medication dispensed to a patient for use off the premises.
[7.32.8.7 NMAC - N, 11-30-05]
7.32.8.8 Approval to Operate an Opioid Treatment Program
Required: Providers
who receive written approval by the department of health, shall be permitted to
provide opioid dependency treatment services.
[7.32.8.8 NMAC - N, 11-30-05]
7.32.8.9 Eligibility
for Approval to Operate an Opioid Treatment Program:
Only applicants who possess all of
the following shall be eligible to receive approval to operate from the
department of health:
A. drug enforcement agency (DEA)
approval to operate an OTP;
B. SAMHSA/CSAT approval to operate an OTP;
C. accreditation by a SAMHSA/CSAT-approved nationally
recognized accreditation body, such as JCAHO or CARF, to operate an OTP:
(1) if the applicant is a start-up program
unable to obtain such accreditation prior to beginning operation because the
accreditation body requires a period of program operation, typically six (6)
months, before it will grant
accreditation:
(a) the department of health shall grant
provisional approval to operate pending accreditation, provided that all other
requirements of these regulations are met; and
(b) the program demonstrates in its
application to the department of health that it is taking the steps necessary
to become accredited as quickly as possible, and provides a timeline for the
anticipated accreditation;
(2) during this interim period, the
provisional approval to operate is contingent on the ongoing progress of the
program, as determined by the department of health, to obtain accreditation
within the timeline contained in the application; the program shall immediately
inform the department of health of anything that will delay or prevent
accreditation according to that timeline;
(3) the department of health shall withdraw
its provisional approval if it concludes that accreditation will not be
forthcoming; in any event, the program shall obtain accreditation within 12
months of beginning operation, or the provisional approval shall be withdrawn,
unless the department of health elects to extend the provisional approval
period after consultation with the appropriate federal and accrediting
entities.
D. a license from the New Mexico state board of pharmacy to
operate an OTP;
E. other permits and licenses such as a business license
from the applicant’s local governmental entity, as required by local
ordinances;
F. evidence of appropriate liability insurance coverage for
the program and its employees.
[7.32.8.9 NMAC - N, 11-30-05]
7.32.8.10 Application
for Approval to Operate an Opioid Treatment Program:
A. Each OTP sponsor applicant shall submit to the department
of health an application for approval to operate an opioid treatment program
application using the form provided by the department of health. This
application shall be in addition to the application to drug enforcement agency,
SAMHSA/CSAT, the NM board of pharmacy, local government, etc.
B. The department of health shall approve or deny the
application within 45 working days of submission, unless the department of
health and applicant mutually agree to extend the application review period.
C. The department of health may require the applicant to
provide additional written or verbal information in order to reach its decision
to grant or deny approval. Such further information shall be considered an
integral part of the application.
D. Approval shall be for a duration of 3 years, except as
otherwise provided below for initial grandfathered approvals.
E. The department
of health shall not grant approval to operate an OTP to any program
sponsor who has been convicted of any crime related to controlled substances
laws or any felony within the last 5 years. No person who has been convicted of
any felony in the last 5 years shall be employed by the OTP in any capacity
that gives that person access to controlled medications.
F. The department of health shall not grant approval to any
entity that poses a risk to the health and safety of the public based on a
history of noncompliance with state and federal regulations as verified by the
DEA, New Mexico state board of pharmacy, FDA, SAMSHA approved accreditation
bodies, or the state licensure agency in any state in which the program sponsor
currently operates.
G. The department of health may deny approval if there is a
documented history of repeated and serious negative neighborhood impact with
respect to other OTP programs currently operated by the program sponsor or by
any corporation, LLC or partnership with whom the program sponsor has been
associated in the past 5 years.
H. As a condition of approval to
operate an OTP, the OTP must maintain or obtain accreditation with a
SAMHSA/CSAT-approved nationally recognized accreditation body, (e.g. CARF or
JCAHO.) In the event that such
accreditation lapses, or approval of an application for accreditation becomes
doubtful, or continued accreditation is subject to any formal or informal
finding of need for improvement, the OTP program will notify the department of health within two business days of
such event. The OTP program will furnish the
department of health with all information related to its accreditation
status, or the status of its application for accreditation, upon request.
I. The application for approval shall
be accompanied by a needs assessment, specifying the proposed geographical area
to be served, estimated number of patients anticipated, and such other
information as may assist the department of health
in review of the application. The department of
health shall take into consideration in making its decision the need for
an OTP in a given geographic area and the impact on the community.
J. The department
of health shall perform on-site inspection of the proposed OTP facility as part
of the review and approval process.
K. In the event of change of ownership of an approved opioid
treatment program, the department of health approval is not transferable; the
new ownership must institute an application for approval as a new program, in
accordance with these regulations.
[7.32.8.10 NMAC - N, 11-30-05]
7.32.8.11 Denial of DOH Approval to Operate; Appeal of Denial:
A. The department of health shall not deny approval to
operate until the applicant has been notified in writing of the deficiency in
the application resulting in the contemplated denial, and given opportunity to
remedy the application deficiency within a specified time period.
B. The department of health shall provide a written
explanation for any denied application. Denial may be appealed to the secretary
of the department of health, whose decision shall be final.
C. An applicant who
is denied approval may re-apply by submitting a new application 90 days or more
after notification of denial.
D. Failure to
complete the application form in its entirety, including requests for
additional information as specified above, shall be grounds for denial of
approval.
[7.32.8.11 NMAC - N, 11-30-05]
7.32.8.12 Renewal of DOH Approval to Operate:
A. OTP providers who wish to renew
their approval shall submit an application form and requested documentation no
less than 90 calendar days, and no more than 180 calendar days, before its
expiration date.
B. The department of
health shall consider the operating history of the OTP provider in making its
determination to grant or deny an application to a previously approved
provider.
[7.32.8.12 NMAC - N, 11-30-05]
7.32.8.13 Approval for OTPs in existence prior to these
Regulations: Opioid
treatment programs operating in New Mexico prior to the effective date of these
regulations shall be granted approval on the effective date of these
regulations (“grandfathered in”).
A. The term of these initial
grandfathered approvals shall be not less than 24 months nor more than 36
months, and may have staggered expiration dates to avoid simultaneous
expiration.
B. “Grandfathered” opioid treatment
programs shall provide the department of health with all written policies,
procedures and other documentation required of new opioid treatment programs
under these regulations within 45 days of the effective date of these
regulations.
[7.32.8.13 NMAC - N, 11-30-05]
7.32.8.14 Renewal of Grandfathered Operating Permits: Renewal
of grandfathered approvals shall follow the ordinary renewal process. Such approvals shall have a term of 36
months.
[7.32.8.14 NMAC - N, 11-30-05]
7.32.8.15 Inspection
Authority: The department of health shall
have the authority to conduct inspections of the records, policies, procedures,
physical plant or any other aspect of an OTP for the purpose of determining its
compliance with these regulations or the presence of any factor posing a danger
to the health or welfare of its patients or the public. Failure of an OTP to
cooperate with such inspection shall be grounds for immediate suspension of the
approval.
[7.32.8.15 NMAC - N, 11-30-05]
7.32.8.16 Noncompliance with Regulations:
A. If an inspection
conducted by the department of health shows that an OTP is not in compliance
with these regulations, the department of health shall deliver to the program a
written notice of the deficiencies identified.
B. The program shall
respond to the notification of deficiencies within 30 days of the notification.
The program response shall include a corrective action plan together with
timeline for implementation, or an explanation, satisfactory to the department
of health, of the reason for any deviations from the requirements of these
regulations.
C. Failure of the
OTP to respond within 30 days of receipt of the notification of deficiencies
shall be grounds for immediate suspension of the approval.
[7.32.8.16 NMAC - N, 11-30-05]
7.32.8.17 Immediate Suspension of OTP
Operating Approval:
A. The department of
health, at its discretion, may immediately suspend the approval of any OTP
found to be in a substantial violation of this regulation that results in
danger to the health and welfare of any patient or of the public, until such
time as the violation (s) are corrected to the satisfaction of the department
of health.
B. In the event of such suspension, the
OPT shall immediately:
(1) cease accepting new patients; and
(2) consult with the department of health
regarding the orderly transfer of patients to other OTPs and implementation of
the program closure action plan required under the “preparedness planning”
section of these regulations in order to minimize adverse impact on its
patients; notwithstanding the suspension of the approval, the department of
health may allow the OTP to conduct limited operations of its program as the
department of health finds necessary to minimize adverse impact on patients.
[7.32.8.17 NMAC - N, 11-30-05]
7.32.8.18 Administration:
The program sponsor shall ensure that:
A. a physician licensed to practice in
New Mexico is designated to serve as medical director and to have authority
over all medical aspects of opioid treatment;
B. the medical director is responsible
for ensuring that the OTP is in compliance with all applicable federal, state
and local laws and regulations;
C. the OTP shall be open for patients every
day of the week except for federal and state holidays, and Sundays, and be
closed only as allowed in advance in writing by CSAT and the state methadone
authority;
D. written policies and procedures are
developed, implemented, complied with and maintained at the OTP and include:
(1) procedures to prevent a
patient from receiving opioid dependency treatment from more than one agency or
physician concurrently;
(2) procedures to meet the
unique needs of diverse populations, such as pregnant women, children,
individuals with communicable diseases, (e.g. hepatitis C, tuberculosis, HIV or
AIDS), or individuals involved in the criminal justice system;
(3) procedures for conducting
a physical examination, assessment and laboratory tests;
(4) procedures for
establishing substance abuse counselor caseloads, based on the intensity and
duration of counseling required by each patient;
(5) criteria for when the
patient’s blood serum levels should be tested and procedures for having the
test performed;
(6) procedures for performing
laboratory tests, such as urine drug screens or toxicological tests, including
procedures for collecting specimens for testing;
(7) procedures for addressing
and managing a patient’s concurrent use of alcohol or other drugs;
(8) procedures for providing
take home medication to patients;
(9)
procedures for conducting opioid treatment withdrawal;
(10) procedures for conducting
an administrative withdrawal;
(11) procedures for voluntary
discharge, including a requirement that a patient discharged voluntarily be
provided or offered follow-up services, such as counseling or a referral for
medical treatment;
(12) procedures for making
temporary or permanent transfer of a patient from the OTP to another OTP;
(13) procedures for receiving the temporary or
permanent transfer of a patient from another OTP to the OTP;
(14) procedures to minimize
the following adverse events:
(a) a patient’s loss of
ability to function;
(b) a medication error;
(c) harm to a patient’s family
member or another individual resulting from ingesting a patient’s medication;
(d) sales of illegal drugs on the premises;
(e) diversion of a patient’s
medication;
(f) harassment or abuse of a
patient by a staff member or another patient; and
(g) violence on the premises;
(15) procedures to respond to
an adverse event, including:
(a) a requirement that the
program sponsor immediately investigate the adverse event and the surrounding
circumstances;
(b) a requirement that the
program sponsor develop and implement a plan of action to prevent a similar
adverse event from occurring in the future; monitor the action taken; and take
additional action, as necessary, to prevent a similar adverse event;
(c) a requirement that action
taken under the plan of action be documented; and
(d) a requirement that the
documentation be maintained at the agency for at least two years after the date
of the adverse event;
(16) procedures for infection
control;
(17) criteria for determining
the amount and frequency of counseling that is provided to a patient; procedures
to ensure that the facility’s physical appearance is clean and orderly;
(18) a
process for resolution of patient complaints, including a provision that
complaints which cannot be resolved through the clinic’s process may be
referred by either party to the department of health:
(a) the complaint process
shall be explained to the patient at
admission;
(b) the patient complaint
process shall be posted prominently in its waiting area or other location where
it will be easily seen by patients, and include the
department of health contact information for use in the event that the
complaint cannot be resolved through the clinic’s process.
E. a written quality assurance plan is
developed and implemented;
F. all information and instructions
for the patient are provided in the patient’s primary language, and, when
provided in writing, are clear and easily understandable by the patient.
[7.32.8.18 NMAC - N, 11-30-05]
7.32.8.19 ADMISSION:
A. The program sponsor shall ensure
through policy and procedure that an individual is only admitted for opioid
dependency treatment after the program medical director determines and
documents that:
(1) the individual meets the
definition of opioid dependence using generally accepted medical criteria such
as those contained in the diagnostic and statistical manual for mental
disorders (DSM-IVor subsequent editions);
(2) the individual has
received a physical examination as required by Subsection D of 7.32.8.19 NMAC
below; and
(3) if the individual is
requesting maintenance treatment, the individual has been addicted for at least
12 months before the admission, unless the individual receives a waiver of this
requirement from the program medical director because the individual:
(a) was released from a penal
institution within the last six months;
(b) is pregnant, as confirmed by the agency
physician;
(c) was treated for opioid
dependence within the last 24 months; or
(d) is under the age of 18,
has had two documented unsuccessful attempts at short term opioid treatment
withdrawal procedures or drug-free treatment within a 12-month period, and has
informed consent for treatment provided by a parent, guardian, custodian or
responsible adult designated by the relevant state authority.
B. A program sponsor shall ensure that
an individual requesting long-term or short-term opioid treatment withdrawal
treatment who has had two or more unsuccessful opioid treatment withdrawal
treatment episodes within a 12-month period is assessed by the program medical
director for other forms of treatment.
C. The OTP shall ensure that each
patient at the time of admission:
(1) provides written,
voluntary, program-specific informed consent to treatment;
(2) is informed of all services that are
available to the patient through the program and of all policies and procedures
that impact the patient’s treatment; and
(3) is informed of the
following:
(a) the progression of opioid
dependency and the patient’s apparent stage of opioid dependence;
(b) the goal and benefits of
opioid dependency treatment;
(c) the signs and symptoms of
overdose and when to seek emergency assistance;
(d) the characteristics of
opioid dependency treatment medication, such as its effects and common side
effects, the dangers of exceeding the prescribed dose, and potential interaction
effects with other drugs, such as other non-opioid agonist treatment
medications, prescription medications, and illicit drugs;
(e) the requirement for a
staff member to report suspected or alleged abuse or neglect of a child or an
incapacitated or vulnerable adult according to state law;
(f) the requirement for a
staff member to comply with the confidentiality requirements of title 42 CFR
part 2 of the code of federal regulations, incorporated by reference;
(g) drug screening and
toxicological testing procedures;
(h) requirements to receive
take-home medication;
(i) testing and treatment
available for HIV and other communicable diseases, the availability of
immunization for hepatitis A and B, and the availability of harm reduction
services;
(j) availability of counseling
on preventing exposure to and transmission of human immunodeficiency virus
(HIV), sexually transmitted diseases, and blood-born pathogens;
(k) the patient’s right to
file a complaint with the program for any reason, including involuntary
discharge, and to have the patient’s complaint handled in a fair and timely
manner.
D. A program sponsor shall ensure that
the program medical director or medical practitioner designee conducts a
complete, fully documented physical examination of an individual who requests
admission to the program before the individual receives a dose of opioid
dependency treatment medication, and that the physical examination includes:
(1) reviewing the individual’s
bodily systems;
(2) obtaining a medical and
family history and documentation of current information to determine chronic or
acute medical conditions such as diabetes, renal diseases, hepatitis, HIV
infection, tuberculosis, sexually transmitted disease, pregnancy or cardiovascular
disease;
(3) obtaining a history of
behavioral health issues and treatment, including any diagnoses and
medications;
(4) initiating the following
laboratory tests:
(a) a mantoux skin test;
(b) a test for syphilis;
(c) a laboratory drug
detection test for at least opioids, methadone, amphetamines, cocaine,
barbiturates, benzodiazepines and other substances as may be appropriate, based
upon patient history and prevailing patterns of availability and use in the
local area;
(5) recommending additional
tests based upon the individual’s history and physical condition, such as:
(a) complete blood count;
(b) EKG, chest X-ray, pap
smear or screening for sickle cell disease;
(c) a test for hepatitis B and
C; or
(d) HIV testing.
(6) the full medical
examination including test results must be completed within 14 days of
admission to the program;
(7) a patient re-admitted
within three months after discharge does not require a repeat physical
examination unless requested by the program medical director.
E. A program sponsor shall ensure that
the results of a patient’s physical examination are documented in the patient
record.
F. A patient may not be enrolled in
more than one OTP program except under exceptional circumstances, such as
residence in one city and employment that requires extended absences from that
city, which must be documented in the patient chart by the medical directors of
both programs:
(1)
an OTP shall make and document good faith efforts to determine that a
patient seeking admission is not receiving opioid dependency treatment
medication from any other source, within the bounds of all applicable patient
confidentiality laws and regulations;
(2) the OTP shall confirm that
the patient is not receiving treatment from any other OTP, except as provided
in Subsection F of 7.32.8.19 NMAC, within a 50 mile radius of its location, by
contacting any such other program, or by using the central registry described
in Subsection G of 7.32.8.19 NMAC, when established.
G. The department of health may
establish an internet-based central registry of all persons in New Mexico who
are current patients of a New Mexico OTP program, for the purpose of creating a
system that prevents patients from surreptitiously receiving medication from
more than one OTP. Each OTP as a condition of approval to operate shall
participate in the central registry as directed by the department
of health.
[7.32.8.19 NMAC - N, 11-30-05]
7.32.8.20 Assessment
and Treatment Plans: The
program sponsor shall ensure that:
A. each patient receives a
comprehensive intake assessment upon admission, conducted by a qualified
professional, to determine the most appropriate combination of services and
treatment, which results in an intake treatment plan based on the patient’s
goals; the results of the comprehensive intake assessment and the intake
treatment plan are documented in the patient record within 24 hours of
admission;
B. an individualized treatment plan
shall replace the intake treatment plan within 30 days of admission or the
third face-to-face contact with the client, and be documented in the patient
record;
C. all updates or revisions to any
treatment plan or assessment shall be documented in the patient record within 7
working days;
D. all assessments and/or treatment
plans shall include, but not necessarily be limited to:
(1) a description of the
patient’s presenting issue, identification of the patient’s behavioral health
symptoms and the behavioral health issue or issues that require treatment;
(2) a list of the medical
services, including medication, needed by the patient, as identified in the
physical examination;
(3) recommendations for
further assessment or examination of the patient’s needs if indicated;
(4) recommendations for
treatment needed by the patient, such as psychosocial counseling or mental
health treatment, if indicated;
(5) recommendations for
ancillary services or other services needed by the patient, if indicated;
(6) the signature,
professional credential, printed name, and date signed of the staff member
conducting and developing the assessment, treatment plan, update or revision;
(7) in the case of updated or
revised treatment plans, a summary of the patient’s progress or lack of
progress toward each goal on the previous plan and the program’s response; and
any new goals;
(8) the signature and date
signed, or documentation of the refusal to sign, of the patient or the
patient’s guardian or agent or, if the patient is a child, the patient’s parent,
guardian, or custodian;
E. treatment plans shall be reviewed
at least every 90 days for the first 2 years of continuous treatment, and at
least every 6 months thereafter, in accordance with the program’s established
policy and procedure, and the treatment plan modified accordingly, except
initial treatment plans must be replaced with individualized plans as provided
for in Subsection B of 7.32.8.20 NMAC above;
F. adequate medical, psychosocial
counseling, mental health, vocational, educational and other assessment and
treatment services are fully and reasonably available to patients, either by
the program directly, or through formal, documented referral agreements with
other providers.
[7.32.8.20 NMAC - N, 11-30-05]
7.32.8.21 DOSAGE:
The
program sponsor shall ensure that:
A. a dose of opioid dependency
treatment medication is administered only after an order from the program
medical director;
B. a patient’s dosage of opioid
dependency treatment medication is individually determined;
C. a dose of opioid dependency
treatment medication is sufficient to produce the desired response in a patient
for the desired duration of time and with consideration for patient safety;
D. a dose of opioid dependency
medication is prescribed to meet a patient’s treatment needs by:
(1) preventing the onset of
subjective or objective signs of withdrawal for 24 hours or more;
(2) reducing or eliminating
the drug craving that is experienced by opioid dependent individuals who are
not in opioid treatment;
(3) a patient receiving
comprehensive maintenance treatment receives an initial dose of opioid
dependency treatment medication based upon the program medical director or
medical practitioner designee’s physical examination and with consideration for
local issues, such as the relative purity of available illicit opioid drugs;
(4) a patient receiving
methadone in comprehensive maintenance treatment receives an initial dose of
methadone that does not exceed 30 milligrams; and
(a) if the patient’s
withdrawal symptoms are not suppressed after the initial dose of 30 milligrams,
a patient receives an additional dose that does not exceed 10 milligrams only
if a program clinician documents in the patient record that 30 milligrams did
not suppress the patient’s withdrawal symptoms; and
(b) if the patient’s
withdrawal symptoms are not suppressed by a total dose of 40 milligrams, a
patient receives an additional dose only if the program medical director or
medical practitioner designee documents in the patient record that 40
milligrams did not suppress the patient’s withdrawal symptoms;
(5) a patient receiving
buprenorphine in opioid treatment withdrawal procedure or comprehensive
maintenance treatment receive an initial dose according to the instructions on
the opioid dependency treatment medication package insert, and any deviation
from the instructions is documented by the program clinician in the patient
record;
(6) a patient receives
subsequent doses of opioid dependency treatment medication:
(a) based on the patient’s
individual needs and the results of the physical examination and assessment;
(b) sufficient to achieve the
desired response for at least 24 hours, with consideration for day-to-day
fluctuations and elimination patterns;
(c) that are not used to reinforce positive
behavior or punish negative behavior;
(d) as long as the patient
benefits from and desires comprehensive maintenance treatment; and
(e) that are adjusted if a
provider changes from one type of opioid dependency treatment medication to another.
[7.32.8.21 NMAC - N, 11-30-05]
7.32.8.22 DRUG
SCREENING: The program sponsor shall ensure that:
A. staff members have knowledge of the
benefits and limitations of laboratory drug detection tests and other
toxicological testing procedures;
B. a patient in comprehensive
maintenance treatment receives at least eight random laboratory drug detection
tests per year; short-term opioid treatment withdrawal procedure patients
receive at least one initial drug abuse test; long-term opioid treatment
withdrawal procedure patients receive an initial and monthly random tests; and
other toxicological tests are performed according to written orders from the
program medical director or medical practitioner designee;
C. laboratory drug detection tests and
other toxicological testing specimens are collected in a manner that minimizes
falsification;
D. laboratory drug detection tests for:
(1) opioids;
(2) methadone;
(3) amphetamines;
(4) cocaine;
(5) barbiturates;
(6) benzodiazepines; and
(7) other substances as may be
appropriate, based upon patient history and prevailing patterns of drug
availability and use in the local area;
E. the results of a patient’s
laboratory drug detection tests or other toxicological test and any action
taken relating to the results are documented in the patient record.
[7.32.8.22 NMAC - N, 11-30-05]
7.32.8.23 TAKE-HOME
MEDICATIONS:
A. The program sponsor shall ensure
that policies and procedures are developed, implemented, and complied with for
the use of take-home medication and include:
(1) criteria for determining
when a patient is ready to receive take-home medication;
(2) criteria for when a
patient’s take-home medication is increased or decreased;
(3) a requirement that take-home medication be
dispensed according to federal and state law;
(4) a requirement that the
program medical director review a patient’s take-home medication regimen at
intervals of no less than 90 days and adjust the patient’s dosage, as needed;
(5) procedures for safe
handling and secure storage of take-home medication in a patient’s home; and
(6) criteria and duration of
allowing a physician to prescribe a split medication regimen.
B. Treatment program decisions on
dispensing OTP medications to patients for unsupervised use, beyond that set
forth in Subsection C of 7.32.8.23 NMAC below, shall be made by the program
medical director, based on the following criteria:
(1) absence of recent abuse of
drugs, including alcohol;
(2) regularity of program
attendance;
(3) length of time in
comprehensive maintenance treatment;
(4)
absence of known criminal activity;
(5) absence of serious
behavioral problems at the program;
(6) special needs of the
patient such as physical health needs;
(7) assurance that take-home
medication can be safely stored in the patient’s home;
(8) stability of the patient’s
home environment and social relationships;
(9) the patient’s work,
school, or other daily activity schedule;
(10) hardship experienced by
the patient in traveling to and from the program; and
(11) whether the benefit the
patient would receive by decreasing the frequency of program attendance
outweighs the potential risk of diversion.
C. A patient in comprehensive
maintenance treatment may receive a single dose of take-home medication for
each day that a provider is closed for business, including Sundays and state
and federal holidays.
D. A program sponsor shall ensure that
take-home medication is only issued to a patient in compliance with the
following restrictions:
(1) during the first 90 days
of comprehensive maintenance treatment, take-home medication is limited to a
single dose each week, in addition to any doses received as described in
Subsection C of 7.32.8.23 NMAC above;
(2) during the second 90 days
of comprehensive maintenance treatment, a patient may receive a maximum of two
doses of take-home medication each week in addition to any doses received as
described in Subsection C of 7.32.8.23 NMAC above;
(3) during the third 90 days
of comprehensive maintenance treatment, a patient may receive a maximum of
three doses of take-home medication each week in addition to any doses received
as described in Subsection C of 7.32.8.23 NMAC above;
(4) in the remaining months of
the patient’s first year, a patient may receive a maximum of 6 days of
take-home medication each week;
(5) after one year of
continuous treatment, a patient may receive a maximum 2-week supply of
take-home medication;
(6) after two years of
continuous treatment, a patient may receive a maximum of one month’s supply of
take-home medication but must make monthly visits;
(7) exceptions to the above
take-home medication restrictions shall be made only as provided for in center
for substance abuse treatment (CSAT) regulations and as approved by the state
methadone authority.
E. A program sponsor shall ensure that
a patient receiving take-home medication receives:
(1) take-home medication in a
child-proof container; and
(2) written and verbal
information on the patient’s responsibilities in protecting the security of
take-home medication.
F. The program sponsor shall ensure
that the program medical director’s determination made under Subsection B of
7.32.8.23 NMAC and the reasons for the determination are documented in the
patient record.
G. In accordance with DEA regulations,
the program shall not use U. S. mail or express services such as fedex or
united parcel service to transport, furnish or transfer opioid treatment
medication to any patient, agency, facility or person.
H. The program shall establish policy
and procedure to provide for the safe and secure transportation of opioid
treatment medication from its facility to another agency where the program’s
patient temporarily resides, (e.g., from the university of New Mexico’s
addiction and substance abuse program (ASAP) to the turquoise lodge treatment
program.).
[7.32.8.23 NMAC - N, 11-30-05]
7.32.8.24 WITHDRAWAL
TREATMENT AND MEDICALLY SUPERVISED DOSE REDUCTION:
The program sponsor shall ensure that:
A. policies and procedures are
developed, implemented, and complied with for withdrawal treatment and:
(1) are designed to promote
successful withdrawal treatment;
(2) require that dose reduction
occur at a rate deemed medically appropriate by the program medical director;
(3) require that a variety of
ancillary services, such as self-help groups, be available to the patient
through the program or through referral;
(4) require that the amount of counseling
available to the patient be increased before discharge; and
(5) require that a patient be
re-admitted to the program or referred to another program if relapse occurs;
B. a patient’s withdrawal treatment:
(1) for a patient involved in
comprehensive maintenance treatment, is only initiated as administrative
withdrawal, or when voluntarily requested by the patient and approved by a
program medical director; and
(2) is planned and supervised
by the program medical director;
C. before a patient begins withdrawal
treatment, whether with or against the advice of the program medical director,
the patient:
(1) is informed by the program medical director
or a medical practitioner designee:
(a) that the patient has the
right to leave opioid treatment at any time; and
(b) of the risks of withdrawal
treatment; and
(2) upon request, receives a
schedule for withdrawal treatment that is developed by the program medical
director with input from the patient;
(3) receives a copy of the
program policy regarding withdrawal of opioid medication against medical advice
and a verbal explanation of that policy;
D. if a patient who is receiving
withdrawal treatment, other than a patient experiencing administrative
withdrawal, appears to a staff member to relapse, the patient is permitted to
begin comprehensive maintenance treatment, if otherwise eligible;
E. if a patient who has completed
withdrawal treatment within the past 30 days appears to a staff member to
relapse, the patient may be re-admitted without a physical examination or
assessment with the consent of the program medical director;
F. a patient experiencing
administrative withdrawal is referred or transferred to any program that is
capable of or more suitable for meeting the patient’s needs, and the referral
or transfer is documented in the patient record;
G. the following information is
documented in the patient record:
(1) the reason that the
patient sought withdrawal treatment or was placed on administrative withdrawal;
and
(2) the information and assistance provided to
the patient in medical withdrawal or administrative withdrawal.
[7.32.8.24 NMAC - N, 11-30-05]
7.32.8.25 COUNSELING
AND MEDICAL SERVICES: The
program sponsor shall ensure that:
A. substance abuse counseling and
behavioral health treatment planning is provided by a practitioner licensed in
the state of New Mexico to provide behavioral health treatment services to each
patient based upon the patient’s individual needs, treatment plan and stage of
readiness to change behavior;
B. the program has substance abuse
counselors in a number sufficient:
(1) to ensure that patients
have access to counselors;
(2) to provide the treatment
in patients’ treatment plans; and
(3) to provide unscheduled
treatment or counseling to patients;
C. each patient seeking opioid
treatment is screened for the presence of a co-occurring mental health disorder
by means approved by the department of health,
and if indicated, referred for assessment and possible treatment if the program
is not able to provide mental health services; an OTP referring a patient to
another provider for mental health assessment shall make and document its good
faith efforts to follow up with that provider on the results of the referral,
and to co-ordinate its treatment with any subsequent treatment by other
providers, within the limits of all applicable laws and regulations pertaining
to release of patient information and confidentiality;
D. a program sponsor shall ensure that
a patient is offered medical, psychiatric and psychological services, if
needed, either at its program or through referral:
(1) if a patient receives
medical, psychiatric or psychological services, from provider(s) not affiliated
with the program, program staff members shall make a good faith effort to
communicate and coordinate its treatment services with such provider, including
monitoring and evaluating interactions between the patient’s opioid treatment
medication and medications used to treat the patient’s mental disorder, if any;
(2) the OTP shall have a
procedure to ensure that such good faith coordination efforts are made, in
accordance with all state and federal laws and regulations for the release of
patient records or information;
E. a program sponsor shall make good
faith efforts to establish effective working relationships with the relevant
behavioral health treatment providers in its patient catchment area in order to
facilitate patient access to the services available through those providers;
F. a program sponsor shall ensure that
a patient has access to a self-help group or support group, such as narcotics
anonymous, either at the agency or through referral to a community group;
G. treatment services are provided by
appropriately licensed staff.
[7.32.8.25 NMAC - N, 11-30-05]
7.32.8.26 DIVERSE
POPULATIONS:
A. The program sponsor shall ensure
that:
(1) opioid treatment is
provided regardless of race, ethnicity, gender, age, or sexual orientation;
(2) the program facility is
compliant with the Americans with Disabilities Act (ADA);
(3) opioid treatment is
provided with consideration for a patient’s individual needs, cultural
background, and values;
(4) provider staff members are
culturally competent;
(5) unbiased language is used
in the provider’s print materials, electronic media, and other training or
educational materials;
(6) HIV testing and education
are available to patients either at the provider or through referral;
(7) a patient who is
HIV-positive and who requests treatment for HIV or AIDS:
(a) is offered treatment for
HIV or AIDS either at the provider or through referral; and
(b) has access to an HIV- or
AIDS-related peer group or support group and to social services either at the
provider or through referral to a community group; and
(8) for patients with a
communicable disease such as HIV, AIDS, or hepatitis C, the provider has a
procedure for transferring a patient’s opioid treatment to a non-program
medical practitioner treating the patient for the communicable disease when it
becomes the patient’s primary health concern;
(9) an individual who requires
administration of opioid treatment medication only for relief of chronic pain
is:
(a) identified during the
physical examination or assessment;
(b) not admitted for opioid
medication treatment; and
(c) referred for medical services; and
(d) for a patient with a
chronic pain disorder who is also physically dependent the OTP makes a good
faith effort to coordinate treatment and services with the medical practitioner
treating the patient for pain management.
B. A program sponsor shall ensure that
a policy and procedure is developed, implemented, and complied with for the
treatment of female patients, to include requirements that:
(1) pregnancy tests shall be
administered and reviewed for all women of childbearing age prior to initiating
a opioid treatment withdrawal procedure or medically supervised withdrawal;
(2) appropriate staff members
be educated in the unique needs of female patients; and
(3) each female patient be
informed about or referred to an appropriate support group, at the provider or
in the community.
C. The program sponsor shall ensure
that a policy and procedure is developed, implemented, and complied with for
the treatment of pregnant patients, to include:
(1) a requirement that
priority be given to pregnant individuals seeking opioid treatment;
(2) a requirement that the
reasons for a pregnant individual’s denial of admission to a provider be
documented;
(3) a requirement that a
pregnant patient be offered prenatal care to include fetal assessment either at
the program or through referral to a non-program medical practitioner;
(4) a requirement that the
program communicate with any non-program medical practitioners who are
providing prenatal care to a pregnant patient, to coordinate opioid treatment
and prenatal care, in accordance with all state and federal laws and
regulations for the release of patient records or information; and document all
such communications in the patient records;
(5) a requirement that a staff
member make a good faith effort to educate a pregnant patient who refuses
prenatal care services on the importance of prenatal care;
(6) a requirement that a staff
member obtain a written refusal of prenatal care services that are offered
either directly by the program or by referral, from a pregnant patient who
refuses such services or referral to such services;
(7) a requirement that a
pregnant patient receiving comprehensive maintenance treatment before pregnancy
be maintained at the pre-pregnancy dose of opioid medication, if effective;
(8) a requirement that a
pregnant patient be monitored by the program medical director to determine if
pregnancy-induced changes in the elimination or metabolization of opioid
treatment medication may necessitate an increased or split dose;
(9) a requirement that
withdrawal treatment:
(a) is strongly advised
against before 14 weeks or after 32 weeks of gestation;
(b) the program medical
director reviews the case before initiating withdrawal and monitor it until
withdrawal is complete;
(10) a requirement that a
pregnant patient discharged from the program be referred to a non-program medical
practitioner and that a staff member document the name, address, and telephone
number of the medical practitioner in the patient record.
D. A program sponsor who is officially
notified by a correctional facility that a patient is in their custody shall
ensure that the program:
(1) makes efforts to obtain
approval from the criminal justice system for the continued treatment of the
patient by the program while the patient is incarcerated; and
(2) if approval is obtained
the program continues to treat the patient while the patient is incarcerated ,
within the limits of the program’s ability to provide such treatment to the
incarcerated patient; and
(3) if approval is not
obtained, the program’s attempts to obtain approval are documented in the
patient’s record.
[7.32.8.26 NMAC - N, 11-30-05]
7.32.8.27 PREPAREDNESS
PLANNING:
A. The program sponsor shall ensure
that the program has:
(1) a written plan to ensure uninterrupted
dispensing of medication in the event of dispensing staff turnover; and
(2) a written agreement with
at least one other provider for the provision of opioid treatment medication to
program patients in the event that the
program is unable to provide services;
(3) 24-hour telephone
answering service or other method to reach the program at all times; and
(4) a list of all patients and
the patients’ dosage requirements available and accessible to program on-call
staff members.
B. A program sponsor shall ensure that
a written plan is developed and implemented for continuity of patient services
if the program is voluntarily or involuntarily closed. Such planning shall
include a disaster plan that addresses unforeseeable circumstances such as
natural disaster or involuntary closure from any cause, and:
(1) includes steps for the
orderly transfer of patients to other programs, individuals, or entities that provide
opioid treatment;
(2) includes procedures for
securing, maintaining, and transferring patient records according to federal
and state law; and
(3) the plan is reviewed and
updated, as appropriate, at least once every 12 months.
[7.32.8.27 NMAC - N, 11-30-05]
7.32.8.28 PATIENT
RECORDS:
A. The OTP program shall establish and
maintain a recordkeeping system that is adequate to document and monitor
patient care. The system shall comply with all federal and state requirements
relevant to OTPs and to confidentiality of patient records.
B. Each patient record shall include:
(1) the results of the
physical examination;
(2) the results of all
assessments;
(3) the treatment plan and all updates or
revisions;
(4) the results of laboratory
tests and a description of any action taken based upon the results;
(5) documentation of the
patient’s current dose and dosage history;
(6) documentation of
counseling provided to the patient;
(7) dates and results of
meetings or conferences regarding the patient’s treatment;
(8) documentation of the
process used and factors considered in making decisions that impact a patient’s
treatment, such as whether to allow take-home medication and the frequency of
laboratory drug detection tests; and
(9) documentation of the agency’s
efforts to learn of multiple opioid treatment program enrollment;
(10) documentation that the
patient has received and understood information regarding the harmful effects
of diversion of opioid treatment medication.
[7.32.8.28 NMAC - N, 11-30-05]
7.32.8.29 COMMUNITY
RELATIONS:
A. A program sponsor shall ensure that
policies and procedures are developed, implemented, and complied with to
educate and promote understanding in the community about opioid treatment and
include:
(1) a mechanism for eliciting input from the
community about the provider’s impact on the community;
(2) a requirement that the
program sponsor or designee interface with community leaders to foster positive
relations;
(3) a requirement that the
program sponsor or designee establish a liaison with community representatives
to share information about the program;
(4) a requirement that the
agency have information on substance abuse and related health and social issues
available to the public;
(5) a mechanism for addressing
and resolving community concerns about opioid treatment or the program’s
presence in the community; and
(6)
a mechanism that addresses getting approval for continued treatment in
treatment or care facilities and correctional facilities.
B. A program sponsor shall ensure that
community relations efforts are documented and are evaluated at least once every
6 months.
C. A program sponsor shall comply with
all valid county and municipal ordinances regarding community relations, and
the department of health may consult with
local governmental entities when enforcing this section.
[7.32.8.29 NMAC - N, 11-30-05]
7.32.8.30 DIVERSION
CONTROL: The
program sponsor shall ensure that a written plan is developed, implemented, and
complied with to prevent diversion of opioid treatment medication from its
intended purpose to illicit purposes.
This plan shall assign specific responsibility to licensed and
administrative staff for carrying out the diversion control measures and
functions described in the plan. The
program shall develop and implement a policy and procedure providing for the
reporting of theft or diversion of medication to the relevant regulatory
agencies, and law enforcement authorities.
[7.32.8.30 NMAC - N, 11-30-05]
HISTORY
OF 7.32.8 NMAC: [RESERVED]